[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487326":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":46,"responsibleParty":80,"collaborators":82,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":32,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":32,"enrollmentInfo":97,"targetDuration":32,"studyType":100,"phases":101,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Western Institute for Veterans Research","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HPV Vaccine","EXPERIMENTAL","0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20",[13],"Biological: Human Papillomavirus 9-valent Vaccine, Recombinant",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20",[19],"Other: Normal Saline",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Human Papillomavirus 9-valent Vaccine, Recombinant","0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20",[9],[27,28],"Gardasil 9","9-valent Gardasil",{"type":6,"name":30,"description":17,"armGroupLabels":31,"otherNames":32},"Normal Saline",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Lowell Nicholson, MD","University of Utah Health Care System","PRINCIPAL_INVESTIGATOR",[39,43],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},"CONTACT","801-581-2121","lowell.nicholson@hsc.utah.edu",{"name":44,"role":40,"phone":41,"phoneExt":32,"email":45},"Jamie Rhoads, MD","jamie.rhoads@hsc.utah.edu",[47,68],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"University of Utah Midvalley Health Center","RECRUITING","Salt Lake City","Utah","84107","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-111.89105,40.76078,{"lat":59,"lon":58},[62,63,64,66],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},{"name":35,"role":37,"phone":32,"phoneExt":32,"email":32},{"name":44,"role":65,"phone":32,"phoneExt":32,"email":32},"SUB_INVESTIGATOR",{"name":67,"role":65,"phone":32,"phoneExt":32,"email":32},"Stephanie Klein, MD",{"facility":69,"status":49,"city":50,"state":51,"zip":70,"country":53,"countryCode":54,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"VA Salt Lake City Health Care System","84148",{"type":56,"coordinates":72},[58,59],{"lat":59,"lon":58},[75,77,78,79],{"name":44,"role":40,"phone":76,"phoneExt":32,"email":45},"801-582-1565",{"name":44,"role":37,"phone":32,"phoneExt":32,"email":32},{"name":35,"role":65,"phone":32,"phoneExt":32,"email":32},{"name":67,"role":65,"phone":32,"phoneExt":32,"email":32},{"type":81,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[83,85],{"name":84,"class":6},"University of Utah",{"name":86,"class":87},"Merck Sharp & Dohme LLC","INDUSTRY","100487326","phase-2-human-papillomavirus-hpv-vaccination-vs-placebo-for-the-treatment-of-refractory-cutaneous-warts-100487326",false,"NCT05625633","Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts","Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial","Inclusion Criteria:\n\n1. Must be able to understand and provide written informed consent\n2. Age 18 or older\n3. Clinical diagnosis of cutaneous warts\n4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)\n\nExclusion Criteria:\n\n1. Untreated cutaneous warts\n2. Anogenital warts\n3. Oral warts\n4. Treatment for cutaneous warts in the past 4 weeks\n5. Active acute illness\n6. Immunosuppression\n7. Known hypersensitivity to HPV vaccination\n8. Subjects may not receive any other investigational treatment\n9. Pregnancy or planned pregnancy during the study period","ALL","18 Years",{"count":98,"type":99},120,"ESTIMATED","INTERVENTIONAL",[102,103],"PHASE2","PHASE3","This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.",[106],"Warts",[108,109,110],"Refractory cutaneous warts","Human Papillomavirus (HPV) Vaccination","HPV vaccine","2024-04-04",{"date":113,"type":114},"2024-04-05","ACTUAL",{"date":116,"type":114},"2024-03-25",{"date":118,"type":99},"2026-12",{"name":5,"class":6},2]